Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression

Blood

Volumn 101, Issue 10, 2003, Pages 3849-3856

  Shaughnessy, John ^b   Jacobson, Joth ^b   Sawyer, Jeff ^b   McCoy, Jason ^b   Fassas, Athanasios ^b   Zhan, Fenghuang ^b   Bumm, Klaus ^b   Epstein, Joshua ^b   Anaissie, Elias ^b   Jagannath, Sundar ^b   Vesole, David ^b   Siegel, David ^b   Desikan, Raman ^b   Munshi, Nikhil ^b   Badros, Ashraf ^b   Tian, Erming ^b   Zangari, Maurizio ^b   Tricot, Guido ^b   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; SOMATOMEDIN RECEPTOR; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE; CHROMOSOME 13; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; GENE MAPPING; HAPLOTYPE; HUMAN; HUMAN CELL; INTERPHASE; MAJOR CLINICAL STUDY; METAPHASE; MOLECULAR DYNAMICS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION; CHROMOSOME ABERRATION; COMPARATIVE STUDY; DNA MICROARRAY; GENETICS; METHODOLOGY; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; DIPLOIDY; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METAPHASE; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TIME FACTORS;

EID: 0038495926     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2873     Document Type: Article

References (37)

1. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86: 4250-4256.
2. Tricot G, Sawyer J, Jagannath S, et al. The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. J Clin Oncol. 1997; 15:2659-2666.
3. Desikan R, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
4. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189-195.
5. Smadja N, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98:2229-2238.
6. Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (≥ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002;116:211-217.
7. Zojer N, Koenigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930.
8. Facon T, Avet-Loiseau H, Guilerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2-microglobulin produce a powerful myeloma staging system for patients receiving high dose therapy. Blood. 2001;97: 1566-1571.
9. Fonseca R, Harrington D, Oken M, et al. Biological and prognostic significance of interphase flourescence in situ hybridization detection of chromosome 13 abnormalities (Δ 13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res. 2002;62:715-720.
10. Barlogie B, Jagannath S, Desikan R, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.
11. Shaughnessy J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003;120:44-52.
12. Sawyer J, Waldron J, Jagannath S, Barlogie B. Cytogenetics findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995; 82:41-49.
13. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966:163-170.
15. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc, Series B. 1972;34: 187-220.
16. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletions in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505-1511.
17. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
18. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128-1140.
19. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98:5116-5121.
20. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A. 2002;99:6567-6572.
21. Fassas A, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041-1047.
22. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854-3859.
23. Wu K, Orme L, Shaughnessy J, Bumm K, Barlogie B, Moore M. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood. In press.
24. Moreau P, Facon T, Leleu Z, et al for the Intergroupe Francophone du Myeloma. Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579-1583.
25. Gruber SB, Ellis NA, Scott KK, et al. BLM heterozygosity and the risk of colorectal cancer. Science. 2002;297:2013.
26. Goss KH, Risinger MA, Kordich JJ, et al. Enhanced tumor formation in mice heterozygous for Blm mutation. Science. 2002;297:2051-2053.
27. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
28. Mabuchi H, Fujii H, Calin G, et al. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res. 2001;61:2870-2877.
29. Migliazza A, Bosch F, Komatsu H, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2098-2104.
30. Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K. Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996;88:2250-2258.
31. Ge N-L, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood. 2002;96:2856-2861.
32. Qiang Y-W, Kopantzev E, Rudikoff S. Insulin-like growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood. 2002;99:4138-4146.
33. Townsley F, Aristarkhov A, Beck S, Hershko A, Ruderman J. Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997; 94:2362-2367.
34. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor ps-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996-5000.
35. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
36. Zangari M, Barlogie B, Prather J, et al. Marked activity also in del 13 multiple myeloma of PS 341 and subsequent thalidomide in a setting of resistance to post-autotransplant salvage therapies [abstract]. Blood. 2002;100:387a.
37. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97:2574-2579.